View Clinical Trial (Medical Research Study)
Cannabinoid Receptor Antagonist Treatment of Cognitive Dysfunction in Schizophrenia
| City: |
|
New Haven |
| State: |
|
Connecticut |
| Zip Code: |
|
06511 |
| Conditions: |
|
Schizophrenia - Schizoaffective Disorder |
| Purpose: |
|
This study is a six-week, randomized, placebo-controlled, fixed dose trial comparing
cannabidiol Vs. placebo added to a stable dose of antipsychotic medications in patients
diagnosed with schizophrenia.
|
| Study Summary: |
|
|
| Criteria: |
|
Inclusion Criteria:
- Schizophrenia or Schizoaffective disorder (DSM-IV SCID-confirmed),
Exclusion Criteria:
- Women who are pregnant, nursing or unwilling to use appropriate birth control
measures during study participation.
|
| NCT ID: |
|
NCT00588731 |
| Primary Contact: |
|
Principal Investigator
Mohini Ranganathan
Yale University
Ashley M Schnakenberg, B.S.
Phone: 203-932-5711 ext. 4485
Email: ashley.schnakenberg@yale.edu
|
| Backup Contact: |
|
N/A |
| Location Contact: |
|
New Haven, Connecticut 06511
United States
There is no listed contact information for this specific location.
Site Status: Recruiting |
| Data Source: |
|
ClinicalTrials.gov |
| Date Processed: |
|
May 19, 2013 |
| Modifications to this listing: |
|
Only selected fields are shown, please use the link
below to view all information about this clinical trial. |
|
Click to view Full Listing
|